Shi Zhifeng Laboratory
Neuro-oncology and Neuroscience
Our Team publications

About us


Our research interests and aims

Gliomas exhibit remarkable genetic heterogeneity, with tumors of the same histological diagnosis often having vastly different clinical outcomes. As the first cancer type selected for both the “The Cancer Genome Project” and “Precision Medicine” initiatives, molecular diagnostics are considered essential for elucidating the genetic heterogeneity of gliomas and are key to improving treatment efficacy.

Our research group has long been dedicated to the molecular pathology of gliomas. We focus on establishing molecular diagnostic systems and developing widely applicable technologies. Our aim is to provide theoretical and technical support for improving glioma diagnosis and treatment standards, as well as formulating strategies for early detection and intervention.

Team


Members of Shi Zhifeng Laboratory

principal investigator

Professor 1

undergraduate students

publications


Our researches and patents

Li H, Cao Y, Ye J, Yang Z, Chen Q, Liu X, Zhang B, Qiao J, Tang Q, Yang H, Li J, Shi ZF*, Mao Y,Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer’s disease, Chemical Engineering Journal, Volume 466, 2023, 143152

Wu G, Shi ZF*, Li Z, Xie X, Tang Q, Zhu J, Yang Z, Wang Y, Wu J, Yu J. Study of radiochemotherapy decision-making for young high-risk low-grade glioma patients using a macroscopic and microscopic combined radiomics model. Eur Radiol. 2023 Oct 27.

Li YQ, Shi ZF*, Shang LY, Tao Q, Tang QS, Krause HJ, Yang SW, Ding GQ, Dong H. Graphene quantum dots-based magnetic relaxation switch involving magnetic separation for enhanced performances of endoglin detection using ultra-low-field nuclear magnetic resonance relaxometry, Sensors and Actuators B: Chemical, Volume 380, 2023, 133389.

Ng HK, Li KK, Chung NY, Chan JY, Poon MF, Wong QH, Kwan JS, Poon WS, Chen H, Chan DT, Shi ZF*, Mao Y. Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories. Brain Pathol. 2022 Sep 27:e13120.

Liu EM, Shi ZF*, Li KK, Malta TM, Chung NY, Chen H, Chan JY, Poon MF, Kwan JS, Chan DT, Noushmehr H, Mao Y, Ng HK. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas. Brain Pathol. 2022 Nov;32(6):e13107.

Recent Highlights


Learn about our latest research
Highlight 4

Integrating Multiplex Immunohistochemistry and Machine Learning for Glioma Subtyping and Prognosis Prediction

April 22,2025

Xu H, Fan Z, Jiang S, Sun M, Chai H, Zhu R, Liu X, Wang Y, Chen J, Wei J, Mao Y, Shi Z. The mIHC-based framework enables rapid glioma classification, facilitating tailored treatment strategies and accurate prognosis prediction, potentially improving patient management and outcomes. Read more in MedComm

Highlight 2

Molecular landscapes of longitudinal NF2/22q and non-NF2/22qmeningiomas

May 23, 2023

Ng HK, Li KK, Chung NY, Chan JY, Poon MF, Wong QH, Kwan JS, Poon WS, Chen H, Chan DT, Shi ZF, Mao Y. Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories. Read more in Brain Pathology

Highlight 3

radiochemotherapy decision-making model for young high-risk low-grade glioma patients

May 20, 2024

Wu G, Shi Z, Li Z, Xie X, Tang Q, Zhu J, Yang Z, Wang Y, Wu J, Yu J. Study of radiochemotherapy decision-making for young high-risk low-grade glioma patients using a macroscopic and microscopic combined radiomics model. Read more in European Radiology

Highlight 1

Intraoperative molecular diagnosis of glioma through combination of radiofrequency signals from ultrasound and deep learning

December 2,2023

Xie X, Shen C, Zhang X, Wu G, Yang B, Qi Z, Tang Q, Wang Y, Ding H, Shi Z, Yu J. Rapid intraoperative multi-molecular diagnosis of glioma with ultrasound radio frequency signals and deep learning. Read more in EBioMedicine

source


Laboratory resources and tools

mIHC calculater

A novel framework for glioma subtyping based on multiplexed immunohistochemistry (mIHC)

More

PRIMEG

Atlas of Primary and Recurrent Immune MicroEnvironment of Glioma (single-cell portal)

More

HKSBC

Hong Kong & Shanghai Brain Consortium led by the brain tumor researchers (HKSBC datasets)

More

our events

  • March 2011

    An Agency is Born

    Lorem ipsum dolor sit amet, consectetur adipisicing elit. Sunt ut voluptatum eius sapiente, totam reiciendis temporibus qui quibusdam, recusandae sit vero unde, sed, incidunt et ea quo dolore laudantium consectetur!

  • December 2012

    Transition to Full Service

    Lorem ipsum dolor sit amet, consectetur adipisicing elit. Sunt ut voluptatum eius sapiente, totam reiciendis temporibus qui quibusdam, recusandae sit vero unde, sed, incidunt et ea quo dolore laudantium consectetur!

  • July 2014

    Phase Two Expansion

    Lorem ipsum dolor sit amet, consectetur adipisicing elit. Sunt ut voluptatum eius sapiente, totam reiciendis temporibus qui quibusdam, recusandae sit vero unde, sed, incidunt et ea quo dolore laudantium consectetur!

  • Be Part
    Of Our
    Story!

Contact Us


Phone

+123 456 7890

Address

No. 12 Middle Urumqi Road, Jing ‘an District, Shanghai